Key Points
- Brendan Luu sold 1,394 shares on Dec. 5 at $14.23 for a total of $19,836.62, trimming his stake by 3.51% to 38,329 shares valued at $545,421.67.
- Enanta opened at $14.60 (52‑week range $4.09–$15.34) with a market cap of $421.4M and a negative P/E after reporting EPS of ($0.87) that beat estimates while revenue slightly missed.
- Analysts show a mixed view but a consensus "Moderate Buy" and an average price target of $20.33, with ratings ranging from sell to buy/overweight.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) insider Scott Rottinghaus sold 798 shares of the company's stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $11,355.54. Following the completion of the transaction, the insider owned 21,792 shares of the company's stock, valued at approximately $310,100.16. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Enanta Pharmaceuticals Stock Up 3.6%
Shares of ENTA stock opened at $14.60 on Friday. The stock has a 50-day simple moving average of $11.89 and a 200 day simple moving average of $9.04. The stock has a market capitalization of $421.36 million, a P/E ratio of -3.81 and a beta of 0.96. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $15.34.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The company had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. On average, sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have issued reports on the company. Evercore ISI cut their price objective on Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating on the stock in a report on Monday, September 15th. Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their target price for the company from $14.00 to $20.00 in a research note on Wednesday, October 1st. JMP Securities lifted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a report on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an "overweight" rating and a $17.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $20.33.
View Our Latest Research Report on ENTA
Hedge Funds Weigh In On Enanta Pharmaceuticals
Several large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC increased its position in Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after buying an additional 5,779 shares during the period. US Bancorp DE acquired a new stake in Enanta Pharmaceuticals during the 1st quarter valued at $36,000. Quarry LP acquired a new position in Enanta Pharmaceuticals in the third quarter worth $81,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Enanta Pharmaceuticals by 103.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company's stock valued at $105,000 after buying an additional 4,454 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company's stock worth $122,000 after buying an additional 1,562 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.
About Enanta Pharmaceuticals
(
Get Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
